Study finds long COVID leaves a distinct immune signature in the blood

Researchers identified a small panel of inflammatory and neurology-related blood proteins that may help distinguish long COVID from recovery or no prior infection, while also showing that booster vaccination did not appear to worsen these protein responses in this cohort. The study also found that immune responses after reinfection differed from those seen after the first SARS-CoV-2 infection, suggesting altered long-term immune behavior in some previously infected individuals.

„Gehirnwäsche“ im Schlaf – das glymphatische System als neues Therapie-Ziel? - Welt-Parkinson-Tag 2026

Schizophrenia study finds new biomarker, drug candidate to treat cognitive symptoms

A new Northwestern University study in humans and mice has discovered a novel biomarker of schizophrenia that could also serve as a new drug candidate to treat the cognitive symptoms of the disorder. Schizophrenia affects .5% of the world’s population, including about two million people in the U.S.